{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:56:57Z","timestamp":1761555417306,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA124435","P30-DK116074","UL1-TR003142"],"award-info":[{"award-number":["P30-CA124435","P30-DK116074","UL1-TR003142"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.cct.2021.106509","type":"journal-article","created":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T03:13:56Z","timestamp":1626405236000},"page":"106509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial"],"prefix":"10.1016","volume":"108","author":[{"given":"Bryan","family":"Bunning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haley","family":"Hedlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha","family":"Purington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vandana","family":"Sundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristopher","family":"Kapphahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Cunanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Upinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitan","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruth","family":"O'Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Nicolls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Springman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Parsonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Levitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manisha","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2021.106509_bb0005","article-title":"Data shows panic and disorganization dominate the study of Covid-19 drugs","author":"Herper","year":"2020","journal-title":"STAT"},{"issue":"6","key":"10.1016\/j.cct.2021.106509_bb0010","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/S2589-7500(20)30086-8","article-title":"A real-time dashboard of clinical trials for COVID-19","volume":"2","author":"Thorlund","year":"2020","journal-title":"Lancet Digit. Health"},{"year":"2020","series-title":"There are Already 72 Drugs in Human Trials for Coronavirus in the US. With Hundreds More on the Way, A Top Drug Regulator Warns We Could Run Out of Researchers to Test Them All","author":"Dunn","key":"10.1016\/j.cct.2021.106509_bb0015"},{"issue":"3","key":"10.1016\/j.cct.2021.106509_bb0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1177\/1740774520988298","article-title":"Clinical trials in a COVID-19 pandemic: shared infrastructure for continuous learning in a rapidly changing landscape","volume":"18","author":"Hedlin","year":"2021","journal-title":"Clin. Trials"},{"key":"10.1016\/j.cct.2021.106509_bb0025","article-title":"NIH to start \u201cflurry\u201d of large studies of potential Covid-19 treatment","author":"Herper","year":"2020","journal-title":"STAT"},{"key":"10.1016\/j.cct.2021.106509_bb0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master protocols to study multiple therapies, multiple diseases, or both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N. Engl. J. Med."},{"year":"2018","series-title":"Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs And Biologics. Draft Guidance for Industry","author":"Food and Drug Administration","key":"10.1016\/j.cct.2021.106509_bb0035"},{"key":"10.1016\/j.cct.2021.106509_bb0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41573-019-0034-3","article-title":"Adaptive platform trials: definition, design, conduct and reporting considerations","volume":"18","author":"The Adaptive Platform Trials Coalition","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cct.2021.106509_bb0045","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1016\/S0140-6736(17)31635-5","article-title":"WHO R&D blueprint: a global coordination mechanism for R&D preparedness","volume":"389","author":"Kieny","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2021.106509_bb0050","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJMsb1905390","article-title":"Creating a framework for conducting randomized clinical trials during disease outbreaks","volume":"382","author":"Dean","year":"2020","journal-title":"N. Engl. J. Med."},{"author":"Recovery","key":"10.1016\/j.cct.2021.106509_bb0055"},{"year":"2020","series-title":"Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment. Guidance for Industry","author":"Food and Drug Administration","key":"10.1016\/j.cct.2021.106509_bb0060"},{"key":"10.1016\/j.cct.2021.106509_bb0065","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J. Am. Stat. Assoc."},{"issue":"14","key":"10.1016\/j.cct.2021.106509_bb0070","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1158\/1078-0432.CCR-08-0325","article-title":"Multi-arm clinical trials of new agents: some design considerations","volume":"14","author":"Freidlin","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.cct.2021.106509_bib71","doi-asserted-by":"crossref","first-page":"7001","DOI":"10.1073\/pnas.2002589117","article-title":"Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells","volume":"117","author":"Matsuyama","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.cct.2021.106509_bib72","doi-asserted-by":"crossref","first-page":"103255","DOI":"10.1016\/j.ebiom.2021.103255","article-title":"Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity","volume":"65","author":"Hoffmann","year":"2021","journal-title":"EBioMedicine"}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421002457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714421002457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:52:11Z","timestamp":1761555131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714421002457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":16,"alternative-id":["S1551714421002457"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2021.106509","relation":{},"ISSN":["1551-7144"],"issn-type":[{"type":"print","value":"1551-7144"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The COVID-19 Outpatient Pragmatic Platform Study (COPPS): Study design of a multi-center pragmatic platform trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2021.106509","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106509"}}